Phase II trial of alternate schedule of chemotherapy as front-line treatment in metastatic non-small cell lung cancer (NSCLC): A single-centre experience

被引：0
|
作者：
Lopez Castro, R. [1 ]
Martin, G. [1 ]
Seijas, R. [1 ]
Bellido, L. [1 ]
del Barco, E. [1 ]
Garcia, R. [1 ]
Martin, T. [1 ]
Castro, E. [1 ]
Leno, R. [1 ]
Cruz, J. [1 ]
机构：
[1] Univ Hosp Salamanca, Salamanca, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
19120
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PHASE II TRIAL OF FIRST-LINE TREATMENT WITH ALTERNATE SCHEDULE OF CHEMOTHERAPY IN METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC). A SINGLE-CENTRE EXPERIENCE. FINAL RESULTS
    Lopez Castro, R.
    Martin, G.
    Bellido, L.
    Seijas, R.
    Garcia, R.
    del Barco, E.
    Martin, T.
    Castro, E.
    Leno, R.
    Cruz, J. J.
    ANNALS OF ONCOLOGY, 2008, 19 : 120 - 120
  • [2] Front-line paclitaxel and topotecan chemotherapy in advanced or metastatic non-small-cell lung cancer: a phase II trial
    G. P. Stathopoulos
    C. Katis
    D. Tsavdaridis
    J. Dimitroulis
    D. Karaindros
    J. Stathopoulos
    E. Dimou
    Cancer Chemotherapy and Pharmacology, 2006, 58 : 555 - 560
  • [3] Front-line paclitaxel and topotecan chemotherapy in advanced or metastatic non-small-cell lung cancer: a phase II trial
    Stathopoulos, G. P.
    Katis, C.
    Tsavdaridis, D.
    Dimitroulis, J.
    Karaindros, D.
    Stathopoulos, J.
    Dimou, E.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (04) : 555 - 560
  • [4] Front-line treatment of advanced non-small cell lung cancer with Docetaxel and Irinotecan: A multicenter phase II trial
    Ziotopoulos, P.
    Mylonaki, E.
    Boukovinas, J.
    Agelidou, M.
    Chandrinos, V.
    Zachariadis, E.
    Varthalitis, J.
    Ardavanis, A.
    Christopoulou, A.
    Georgoulias, V.
    ANNALS OF ONCOLOGY, 2004, 15 : 178 - 178
  • [5] Front-line treatment of advanced non-small cell lung cancer with docetaxel and Gemcitabine: A multicenter phase II trial
    Georgoulias, V
    Kourousis, C
    Kakolyris, S
    Dimopoulos, MA
    Papadakis, E
    Apostolopulou, F
    Agelidou, A
    Tzianni, V
    Sarra, E
    Vardakis, N
    ANNALS OF ONCOLOGY, 1998, 9 : 94 - 94
  • [6] FRONT-LINE CHEMOTHERAPY WITH OR WITHOUT NGR-HTNF IN NON-SMALL CELL LUNG CANCER (NSCLC)
    Gregorc, V.
    Zilembo, N.
    Grossi, F.
    De Pas, T.
    Pietrantonio, F.
    Giovannini, M.
    Rossoni, G.
    Bulotta, A.
    Lambiase, A.
    Bordignon, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 410 - 410
  • [7] Front-line weekly chemotherapy with gemcitabine for unfit patients with non-small cell lung cancer (NSCLC)
    Ferrigno, D
    Buccheri, G
    LUNG CANCER, 2004, 45 (03) : 373 - 380
  • [8] Pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC): A phase II clinical trial.
    McCleod, M
    Treat, J
    Christiansen, NP
    Mintzer, DM
    Bonomi, P
    Bloss, LP
    Taylor, L
    Monberg, MJ
    Ye, Z
    Obasaju, CK
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 650S - 650S
  • [9] Pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients (Pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC): A phase II clinical trial.
    West, H
    Belt, RJ
    Wakelee, HA
    Bloss, LP
    Taylor, L
    Monberg, MJ
    Ye, Z
    Obasaju, CK
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 649S - 649S
  • [10] Front-line treatment of advanced non-small cell lung cancer with irinotecan and docetaxel: A multicentre phase II study
    Ziotopoulos, P
    Androulakis, N
    Mylonaki, E
    Chandrinos, V
    Zachariadis, E
    Boukovinas, I
    Agelidou, A
    Kentepozidis, N
    Ignatiadis, M
    Vossos, A
    Georgoulias, V
    LUNG CANCER, 2005, 50 (01) : 115 - 122
12345